转移性去势抵抗性前列腺癌诊断时风险分层可预测总生存并辅助治疗决策:日本多中心协作研究
本研究基于两个独立队列(推导队列196例、外部验证队列211例)评估转移性去势抵抗性前列腺癌(mCRPC)诊断时基于三个预测因子的风险分层系统。三个风险因素为:初始雄激素剥夺治疗至mCRPC诊断持续时间<12个月、mCRPC诊断时碱性磷酸酶>350 U/dL、血红蛋白<11 g/dL。零、一个和多个风险因素分别归为有利、中间和不良风险组,各组中位总生存(OS)在推导和验证队列中均分离良好(P < 0.001)。
要点
- mCRPC诊断时三个风险因素:ADT持续时间<12个月、ALP>350 U/dL、Hb<11 g/dL。
- 零、一、多个风险因素分别对应有利、中间、不良风险组,各组OS分离良好。
- 不良风险组中位OS为12个月,一线多西他赛较ASI有OS延长趋势(17 vs 12个月)。
核心结论
- 基于三个风险因素的新风险分层系统可在mCRPC诊断时预测患者生存。
- 风险定义简便,鼓励医生在日常实践中考虑这些风险分组。
研究设计与样本
- 多中心协作研究,使用两个独立临床队列:推导队列196例mCRPC患者,外部验证队列211例mCRPC患者。
- 患者接受雄激素信号抑制剂(ASI:阿比特龙和恩扎卢胺)或多西他赛作为mCRPC一线治疗。
主要发现
- 三个独立OS预测因子被定义为风险因素:初始ADT至mCRPC诊断持续时间<12个月、mCRPC诊断时ALP>350 U/dL、Hb<11 g/dL。
- 零、一个和多个风险因素分别归为有利、中间和不良风险组。
- 各风险组中位OS在推导队列(P < 0.001)和验证队列(P < 0.001)中均分离良好。
- 总共407例mCRPC患者中,84例归为不良风险组,中位OS为12个月。
- 不良风险组中,一线多西他赛较ASI有OS延长趋势(中位17个月 vs 12个月)。
关键数值与推荐
- 风险因素:初始ADT至mCRPC诊断持续时间<12个月。
- 风险因素:mCRPC诊断时ALP>350 U/dL。
- 风险因素:mCRPC诊断时Hb<11 g/dL。
- 风险分组:零个风险因素为有利组,一个为中间组,多个为不良组。
- 不良风险组(84例)中位OS为12个月;该组一线多西他赛与ASI中位OS分别为17个月和12个月。
临床怎么用
- 在mCRPC诊断时使用三个简便风险因素进行风险分层,辅助治疗决策。
- 不良风险组可考虑一线多西他赛,但需注意仅为趋势观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess whether a new risk stratification system according to predictors for overall survival (OS) at the diagnosis of metastatic castration-resistant prostate cancer (mCRPC) could determine treatment outcomes and assist in treatment decision-making. PATIENTS AND METHODS: Two independent clinical cohorts of patients, treated with androgen signalling inhibitors (ASIs: abiraterone and enzalutamide) or docetaxel as a first-line treatment for mCRPC, were used in this study: a derivation cohort (196 patients with mCRPC) and an external validation cohort (211 patients with mCRPC). RESULTS: Three independent predictors for OS, including duration of initial androgen deprivation therapy <12 months before mCRPC diagnosis, alkaline phosphatase level >350 U/dL and haemoglobin level <11 g/dL at the diagnosis of mCRPC, were defined as risk factors. Patients with zero, one and multiple risk factors were assigned to a favourable-, intermediate- and poor-risk group, respectively. The median OS values in each risk group were well separated in the derivation cohort (P < 0.001) as well as in the validation cohort (P < 0.001). Of a total of 407 patients with mCRPC, 84 were assigned to the poor-risk group with the median OS of 12 months. In this group, a trend towards longer OS favouring docetaxel compared to ASIs as the first-line treatment (medians of 17 and 12 months, respectively) was observed. CONCLUSION: The new risk group stratification system could predict patient survival at the diagnosis of mCRPC. Given the convenience of these risk definitions, physicians may be encouraged to consider these risk groups in daily practice.
引用
- Uchimoto T, Komura K, Fukuokaya W, et al. Risk stratification for the prediction of overall survival could assist treatment decision-making at diagnosis of castration-resistant prostate cancer: a multicentre collaborative study in Japan. BJU Int. 2020. PMID: 32701219. doi:10.1111/bju.15187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。